Company Seeks License to Import LSD Into U.S.
Published Date: 7/16/2026
Notice
Summary
Catalent Greenville, Inc. wants to become an official importer of some powerful controlled substances, including LSD and related drugs. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 17, 2026. This move could impact how these substances enter the U.S., but no costs or fees are mentioned yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Commercial finished-dose imports not authorized
The notice says approval will not allow Catalent to import FDA-approved or non‑approved finished dosage forms for commercial sale. The registration, if issued, would be limited to the listed drug codes and to imports for research, clinical trials, and analytical purposes only.
Import approval sought for Schedule I drugs
On June 4, 2026, Catalent Greenville, Inc. applied to be registered to import lysergic acid diethylamide (LSD, drug code 7315), 3,4-methylenedioxymethamphetamine (MDMA, drug code 7405), and psilocybin (drug code 7437). The company says it plans to import these Schedule I substances for dosage-formulation development for research, clinical trial studies, and analytical purposes.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-14136 — Barlow St-Clair Lynch, M.D.; Decision and Order
Dr. Barlow St-Clair Lynch from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately, impacting his medical practice and any related income.
2026-14135 — David Enright, M.D.; Decision and Order
Dr. David Enright from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-14137 — Shane Lydon, M.D.; Decision and Order
Dr. Shane Lydon's license to handle controlled substances in Maine has been revoked because he lost his state authority and didn’t ask for a hearing. This means he can no longer prescribe or manage these drugs, effective immediately. Anyone relying on his registration should update their records and note this change to avoid legal trouble.
2026-13989 — Mark Allen, D.D.S.; Decision and Order
Mark Allen, D.D.S., lost his DEA registration because he no longer has permission to handle controlled substances in Oklahoma. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately, impacting his dental practice and any related income.
Previous / Next Documents
Previous: 2026-14285 — Importer of Controlled Substances Application: Unither Manufacturing LLC
Unither Manufacturing LLC wants to become an official importer of a controlled drug called methylphenidate, which is used to treat conditions like ADHD. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 17, 2026. This move could affect how this medicine gets into the U.S., but no direct costs or changes for the public are expected right now.
Next: 2026-14287 — Prestressed Concrete Steel Wire Strand From Argentina, Colombia, Egypt, Indonesia, Italy, Malaysia, Netherlands, Saudi Arabia, South Africa, Spain, Taiwan, Tunisia, Turkey, Ukraine, and United Arab Emirates; Scheduling of Full Five-Year Reviews
The U.S. International Trade Commission is checking if special taxes on prestressed concrete steel wire strand from 16 countries should stay or go. This review affects importers, manufacturers, and anyone using this steel wire, with decisions that could impact prices and trade rules soon. The full review started in July 2026 and will decide if these duties protect U.S. businesses from harm or if they can be lifted.